We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA has delayed its decision on expanded use of OSI Pharmaceuticals’ Tarceva by 90 days — to April 18 — after receiving additional data from the company.